AarXiv2019

Tumor Microenvironment-based Gene Signatures Divides Novel Immune and Stromal Subgroup Classification of Lung Adenocarcinoma

Zihang Zeng, Jiali Li, Nannan Zhang, Xueping Jiang, Yanping Gao, Liexi Xu, Xingyu Liu, Jiarui Chen, Yuke Gao, Linzhi Han, Jiangbo Ren, Yan Gong, Conghua Xie

Abstract

'Liexi Xu' 'Xingyu Liu' 'Jiarui Chen' 'Yuke Gao' 'Linzhi Han' 'Jiangbo Ren' 'Yan Gong' 'Conghua Xie'] Keywords: Tumor Microenvironment; Bioinformatics; Machine learning; Immunity; stroma Additional information: This study was supported by National Natural Science Foundation of China [81372498, 81572967, 81773236, and 81800429]; National Project for Improving the Ability of Diagnosis and Treatment of Difficult Diseases, National Key Clinical Speciality Construction Program of China [[2013]544]; the Fundamental Research Funds for the Central Universities [2042018kf0065 and 2042018kf1037]; Health Commission of Hubei Province Scientific Research Project [WJ2019H002 and WJ2019Q047]; Wuhan City Huanghe Talents Plan, and Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund [znpy2016050, znpy2017001, znpy2017049, and znpy2018028].

§ The Valyu brief

The paper, in five minutes

Read from the full text via Valyu Contents

A tumor‑microenvironment model classifies lung adenocarcinoma into four subgroups and predicts survival and immunotherapy response.

What’s new

i.Integrated immune and stromal signatures to define novel lung adenocarcinoma subgroups
ii.Classified tumors into four groups with distinct mutation, cellular, and survival profiles, validated in six independent datasets (1551 patients)
iii.Developed the PMBT prognostic model to predict overall survival and immunotherapy response

How they did it

The study combined immune and stromal gene signatures using eigendecomposition and extraction algorithms such as non‑negative matrix factorization and multitask learning. These methods clustered tumors into four groups based on activation levels of immunity and stroma.

What they found

Four tumor groups identified with differing mutation landscapes and prognoses
Validation across six independent datasets comprising 1551 patients
High‑immune/low‑stromal group showed better overall survival
PMBT model predicts overall survival and immunotherapy response

§ The Valyu brief

Reading the full paper and taking notes. This takes a few seconds…

§ Ask this paper

Ask a question about this paper

Valyu reads the full text and answers from what the paper actually says.

§ Related work in other archives

Similar papers in all four archives

The same idea searched in arXiv, PubMed, bioRxiv and chemRxiv at once, so a method can lead you to where it is being applied.

AarXiv4 found

PPubMed4 found

BbioRxiv4 found

CchemRxiv2 found

Searching the other archives…